Veradigm is a health information services business based in the US. Veradigm shares (MDRX) are listed on the NASDAQ and all prices are listed in US Dollars. Veradigm employs 8,000 staff and has a trailing 12-month revenue of around $1.5 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $9.65 |
|---|---|
| 52-week range | $5.01 - $14.09 |
| 50-day moving average | $9.07 |
| 200-day moving average | $9.72 |
| Wall St. target price | $11.40 |
| PE ratio | 11.5116 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.86 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.65 from 2024-07-25
| 1 week (2024-07-19) | -2.53% |
|---|---|
| 1 month (2024-06-26) | 9.65 |
| 3 months (2024-04-26) | 21.23% |
| 6 months (2024-01-26) | 2.66% |
| 1 year (2023-07-26) | -27.72% |
|---|---|
| 2 years (2022-07-26) | -37.78% |
| 3 years (2021-07-26) | 17.24 |
| 5 years (2019-07-26) | 10.54 |
Valuing Veradigm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Veradigm's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Veradigm's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 12x. In other words, Veradigm shares trade at around 12x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Veradigm's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.4237. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Veradigm's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Veradigm's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $115.4 million.
The EBITDA is a measure of a Veradigm's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.5 billion |
|---|---|
| Operating margin TTM | 16.59% |
| Gross profit TTM | $738.3 million |
| Return on assets TTM | 2.16% |
| Return on equity TTM | 8.93% |
| Profit margin | 3.97% |
| Book value | $10.77 |
| Market Capitalization | $1.1 billion |
TTM: trailing 12 months
We're not expecting Veradigm to pay a dividend over the next 12 months.
Over the last 12 months, Veradigm's shares have ranged in value from as little as $5.01 up to $14.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veradigm's is 0.627. This would suggest that Veradigm's shares are less volatile than average (for this exchange).
Veradigm Inc. , a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising Practice Management software, AI Patient Scheduling Software, and Electronic Statements and Payments; revenue cycle management solutions, including Revenue Cycle Services and revenue cycle management clearinghouse; electronic health records solutions, which include ePrescribe with EPCS, EHR software, Veradigm HER, and Practice Fusion HER; and Patient Engagement Platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as Veradigm Connect, Veradigm App Expo, and Diagnostic Ordering and Resulting Network; Channel Partner Program; and Veradigm ePrescribe Enterprise. In addition, the company offers solutions to health plans and payers, comprising risk adjustment solutions, such as Health Equity Analytics, Risk Adjustment Analytics, Risk Mitigator, Comprehensive Submissions, and Utilization Analytics; quality management solutions, which include quality analytics and risk adjustment and quality management; data exchange+coding solutions, including eChart Courier, eChart Coder, and eChart Integration and Analytics; provider engagement and Veradigm Payer Insights; and Veradigm Payerpath solutions. Further, it provides solutions to biophama, including real world data solutions, such as real world and health data sets and cardiology and metabolic registries; real world evidence and Real World Evidence Analytics Platform; therapy focused solutions, such as cardiovascular, central nervous system, metabolic, and immunology data; and Digital Health Media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc.
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.